Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron variant.
News
What can patent data reveal about global progress in green innovation, and what might be achieved in years to come?
Appleyard Lees’ inaugural ‘Inside Green Innovation: Progress Report 2021’, analyses patent filings across several areas of green innovation, including food and agriculture, bioplastics and plastics recycling, and renewable energy storage.
AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre (DISC) in Cambridge, UK – a state-of-the-art research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.
Drawing upon over 30-years’ experience of serving the glycobiology research community - AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.
Are you building an innovative and emerging life science or biotech
start-up?
Now is your opportunity to accelerate your research and transform it into meaningful value for patients by
applying for an Astellas Future Innovator Prize.
Astellas is oering up to two Future Innovator Prizes for a pioneering science and technology platform
that would be a game-changing approach in Astellas’ interest areas including Blindness & Regeneration,
Mitochondria Biology, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas
OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, during an event last week at Seoul Yeouido SHIC tower, Seoul, South Korea.
15 start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) programme at Stevenage Bioscience Catalyst (SBC), one of Europe’s most important science parks for life sciences. The course was tailored to give data-focused biotech start-ups the skills they need to get potential new drugs and therapies to market more quickly. It was supported by SBC’s community of biotech leaders who shared their expertise through this unique programme focused on the intersection of data analytics and drug discovery.
Cambridge, UK, 17th November 2021: Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.
A £375 million investment to improve understanding and treatment for a range of neurodegenerative diseases.
Funding includes at least £50 million for motor neurone disease (MND) related research to find a cure
New National Institute for Health Research (NIHR) Motor Neurone Disease Research Unit to attract more innovative research applications
People living with neurodegenerative diseases could live longer, healthier lives due to innovative new research, following a government commitment to invest £375 million over the next 5 years.
Drawing upon over 30-years’ experience of serving the glycobiology research community - AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.